



Pfizer Announces an [Independent Medical Education Grant RFP](#)
Increasing the understanding of the impact of underlying medical conditions and other risk factors in people who are at increased risk of developing severe outcomes of COVID-19

Competitive Grant Program - internal Pfizer review process

I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all **independent medical education grants**, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

II. Eligibility

Geographic Scope:	European countries
Applicant Eligibility Criteria	<ul style="list-style-type: none"> • Patient organizations (patient advocacy groups, patient associations) and relevant organizations providing education to the general public are encouraged to apply. In addition, professional associations and medical societies and other entities with a mission related to patient education may apply. We have a high interest in receiving applications for programs that will be led or co-led by representatives from patient advocacy groups or patient associations. • If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. all institutions must have a relevant role and the requesting organization must have a key role in the project.

III. Requirements

Date RFP Issued	<ul style="list-style-type: none"> • 23 August 2022
Clinical Area	<ul style="list-style-type: none"> • COVID-19
General Area of Interest for this RFP:	<p>Through this RFP it is our intent to support education programs aimed at the general public or specific patient groups, for example in those with specific comorbidities, to increase the understanding of the impact of characteristics and comorbidities on a person's risk of developing severe COVID-19 and the importance of the early diagnosis and early treatment, if indicated, in categories of patients at increased risk of severe COVID-19.</p> <p>The specific patient groups would include those with particular comorbidities, underlying medical conditions or characteristics which place them at increased risk of developing severe COVID-19.</p> <p>There are numerous risk factors, including certain underlying medical conditions, placing individuals at increased risk for severe COVID-19. These include¹: increased age, underlying health conditions such as diabetes, obesity, hypertension, history of heart failure, ischaemic heart disease, chronic respiratory disease, chronic kidney disease, immune compromised status, cancer, neurological conditions, smoking and pregnancy. The list is not exhaustive and updates are expected as the science evolves.</p> <p>Projects that will be considered for Pfizer support will address one or more of the following:</p> <ul style="list-style-type: none"> - increase understanding of a person's risk profile and which comorbidities or

	<p>characteristics increase a person’s risk of developing severe COVID-19;</p> <ul style="list-style-type: none"> - increase awareness on the importance of early testing after exposure to SARS-CoV-2 or in presence of suspected COVID-19 signs or symptoms; - educate on the importance of treatment options available for patients with COVID-19 and at increased risk of developing severe disease; - understand the needs of increased risk populations and defining the best channels to engage and communicate with them. <p>Given the current circumstances, programs that can be developed and launched rapidly will be prioritized.</p> <p>Projects that span multiple European countries and include multiple European languages are encouraged.</p> <p>References</p> <p>(1) ECDC - Risk factors and risk groups - [Online] Available from: https://www.ecdc.europa.eu/en/covid-19/latest-evidence/risk-factors-risk-groups. Accessed: July 2022</p> <p><i>It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.</i></p>
<p>Target Audience:</p>	<ul style="list-style-type: none"> • Patients, caregivers, patient organizations and associations, relevant organizations providing education to general public
<p>Expected Approximate Monetary Range of Grant Applications:</p>	<ul style="list-style-type: none"> • Individual projects requesting up to \$100000 will be considered. The estimated total available budget related to this RFP is \$600000.
<p>Key Dates:</p>	<ul style="list-style-type: none"> • RFP release date: 23 August 2022 • Grant Application due date: 22 September 2022 • Please note the deadline is 23:59 Eastern Standard Time (e.g. New York, GMT -5). • Anticipated Grant Award Notification Date: October 2022 • Grants will be distributed following a fully executed agreement. • Anticipated Project Start and End Dates: From December 2022 onwards, with a project duration of 1 year.
<p>How to Submit:</p>	<ul style="list-style-type: none"> • Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Create your password”. [Note: there are individual portals for each grant application type (e.g., knowledge, LOI, research full

	<p><i>proposal, and QI full proposal). Please be sure to use the URL above.]</i></p> <ul style="list-style-type: none"> • Click the “Start A New Knowledge Gap Application” button. • In the application: <ul style="list-style-type: none"> ○ For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP) ○ For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?” select Yes ○ Select the following Competitive Grant Program Name: 2022 HBU EU : Increasing the understanding of the impact of underlying medical conditions and other risk factors in people who are at higher risk of developing severe outcomes of COVID-19 <p>Requirements for submission:</p> <p>Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.</p> <ul style="list-style-type: none"> • If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page. <p>IMPORTANT: Be advised applications submitted after the due date will not be reviewed by the committee.</p>
<p>Questions:</p>	<ul style="list-style-type: none"> • If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Ai Ping Lee (AiPing.Lee@pfizer.com), with the subject line “2022 HBU EU : Increasing the understanding of the impact of underlying medical conditions and other risk factors in people who are at higher risk of developing severe outcomes of COVID-19 , August 2022”.
<p>Grant Agreements:</p>	<ul style="list-style-type: none"> • If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement. • Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.
<p>Review and Approval Process</p>	<ul style="list-style-type: none"> • Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

Appendix A

General RFP Submission Requirements

Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

Goals and Objectives	<ul style="list-style-type: none"> Briefly state the overall goal of the project. List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
Needs Assessment for the Project	<ul style="list-style-type: none"> Include a description of your organization’s needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
Target Audience	<ul style="list-style-type: none"> Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
Project Design and Methods	<ul style="list-style-type: none"> Describe the planned project, the educational approach, and the way the planned methods address the established need.
Innovation	<ul style="list-style-type: none"> Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.
Evaluation and Outcomes	<ul style="list-style-type: none"> In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.
Dissemination Plan	<ul style="list-style-type: none"> Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline	<ul style="list-style-type: none">• Provide an anticipated timeline for your project including project start/end dates.
Additional Information	<ul style="list-style-type: none">• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.
Organization Detail	<ul style="list-style-type: none">• Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.
Budget Narrative	<ul style="list-style-type: none">• Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application• While estimating your budget please keep the following items in mind:<ul style="list-style-type: none">○ Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).○ Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please click here for details.